A Phase 1 interventional study of Ramucirumab - IV and Placebo - IV in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer.
In this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under the skin. Study doctors will measure the amount of ramucirumab in the bloodstream.
Side effects and tolerability will be documented. The study will last for about 16 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of placebo administered IV.
Drug: Placebo - IV
Participants received single 350 milligram (mg) ramucirumab administered as a 60-minute intravenous infusion at a concentration of 10 milligram per millilitre (mg/mL) as one 35 mL infusion.
Drug: Ramucirumab - IV
Participants received single dose of placebo administered SC.
Drug: Placebo - SC
Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as one 2 mL injection.
Drug: Ramucirumab - SC
Participants received single 350 mg ramucirumab SC administered at a concentration of 87.5 mg/mL as two 2 mL injections.
Drug: Ramucirumab - SC
Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 1 mL injections.
Drug: Ramucirumab - SC
Participants received single 700 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 2 mL injections.
Drug: Ramucirumab - SC
Administered IV.
Also known as: LY3009806
Administered IV.
Administered SC.
Also known as: LY3009806
Administered SC.
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, risk of death), persistent or significant disability/incapacity, congenital anomaly/birth defect, Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Day 90
Number of Participants With Injection Site Reactions (ISRs) Following Subcutaneous (SC) Administration of Study Drug
Number of participants showing ISRs when the drug was administered subcutaneously were reported.
Time frame: Day 1 Predose through Day 90
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Ramucirumab
PK: AUC\[0-∞\] of Ramucirumab.
Time frame: 1, 8, 24, 48, 72, 96, 120, 144, 168, 264, 336, 504 hours post-dose
PK: Maximum Concentration (Cmax) of Ramucirumab
PK: Cmax of Ramucirumab
Time frame: 1, 8, 24, 48, 72, 96, 120, 144, 168, 264, 336, 504 hours post-dose
| Milestone | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) |
|---|---|---|---|---|---|---|---|
| Started | 3 | 7 | 12 | 7 | 7 | 7 | 7 |
| Received at least one dose of study drug | 3 | 7 | 12 | 7 | 7 | 7 | 7 |
| Completed | 3 | 6 | 12 | 6 | 6 | 7 | 7 |
| Not completed | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, risk of death), persistent or significant disability/incapacity, congenital anomaly/birth defect, Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Participants | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) |
|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
Number of participants showing ISRs when the drug was administered subcutaneously were reported.
| Participants | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) |
|---|---|---|---|---|---|
| Number of Participants With Injection Site Reactions (ISRs) Following Subcutaneous (SC) Administration of Study Drug | 3 | 3 | 2 | 1 | 1 |
PK: AUC\[0-∞\] of Ramucirumab.
| hour*microgram per milliliter (h*μg/mL) | 350 mg Ramucirumab IV | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Ramucirumab | 18700 ± 19 | 5250 ± 48 | 5140 ± 76 | 6350 ± 57 | 14200 ± 76 |
PK: Cmax of Ramucirumab
| μg/mL | 350 mg Ramucirumab IV | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) |
|---|---|---|---|---|---|
| PK: Maximum Concentration (Cmax) of Ramucirumab | 116 ± 11 | 24 ± 56 | 20.2 ± 63 | 21 ± 66 | 46.7 ± 44 |
Collected over Baseline up to Day 90. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo IV | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| 350 mg Ramucirumab IV | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Placebo SC | 0/12 (0%) | 1/12 (8.3%) | 1/12 (8.3%) |
| 350 mg Ramucirumab SC (1x2 mL) | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| 350 mg Ramucirumab SC (2x2 mL) | 0/7 (0%) | 1/7 (14.3%) | 2/7 (28.6%) |
| 350 mg Ramucirumab SC (2x1 mL) | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| 700 mg Ramucirumab SC (2x2 mL) | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Event | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) |
|---|---|---|---|---|---|---|---|
| Peritonsillar abscessInfections and infestations | 0/3 | 0/7 | 0/12 | 0/7 | 1/7 | 0/7 | 0/7 |
| Pharyngitis streptococcalInfections and infestations | 0/3 | 0/7 | 0/12 | 0/7 | 1/7 | 0/7 | 0/7 |
| TonsillitisInfections and infestations | 0/3 | 0/7 | 0/12 | 0/7 | 1/7 | 0/7 | 0/7 |
| Alcohol withdrawal syndromePsychiatric disorders | 0/3 | 0/7 | 1/12 | 0/7 | 0/7 | 0/7 | 0/7 |
| Event | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/3 | 4/7 | 1/12 | 0/7 | 1/7 | 0/7 | 2/7 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/3 | 0/7 | 0/12 | 0/7 | 0/7 | 0/7 | 0/7 |
| Excessive cerumen productionEar and labyrinth disorders | 0/3 | 0/7 | 0/12 | 1/7 | 0/7 | 0/7 | 0/7 |
| Aphthous ulcerGastrointestinal disorders | 0/3 | 0/7 | 0/12 | 0/7 | 0/7 | 1/7 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/7 | 0/12 | 0/7 | 1/7 | 0/7 | 1/7 |
| DyspepsiaGastrointestinal disorders | 0/3 | 1/7 | 0/12 | 0/7 | 0/7 | 0/7 | 0/7 |
| NauseaGastrointestinal disorders | 0/3 | 0/7 | 0/12 | 0/7 | 0/7 | 1/7 | 1/7 |
| ToothacheGastrointestinal disorders | 0/3 | 1/7 | 0/12 | 0/7 | 0/7 | 0/7 | 0/7 |
| Feeling hotGeneral disorders | 0/3 | 0/7 | 0/12 | 0/7 | 0/7 | 1/7 | 0/7 |
| Injection site bruisingGeneral disorders | 0/3 | 0/7 | 0/12 | 0/7 | 0/7 | 1/7 | 0/7 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 34 (28 to 53) | 35 (20 to 54) | 37 (21 to 58) | 51 (24 to 59) | 46 (26 to 56) | 39 (21 to 60) | 41 (22 to 53) | 40 (20 to 60) |
| Sex: Female, Male(Participants) | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 2 | 2 | 2 | 0 | 1 | 9 |
| Male | 3 | 5 | 10 | 5 | 5 | 7 | 6 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 7 | 4 | 4 | 2 | 1 | 23 |
| Not Hispanic or Latino | 1 | 4 | 5 | 3 | 3 | 5 | 6 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 | 0 | 2 | 2 | 2 | 12 |
| White | 2 | 4 | 8 | 6 | 5 | 5 | 5 | 35 |
| More than one race | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo IV | 350 mg Ramucirumab IV | Placebo SC | 350 mg Ramucirumab SC (1x2 mL) | 350 mg Ramucirumab SC (2x2 mL) | 350 mg Ramucirumab SC (2x1 mL) | 700 mg Ramucirumab SC (2x2 mL) | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 3 | 7 | 12 | 7 | 7 | 7 | 7 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in May 2021, 9 months.
Results were first posted in Feb 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab